Prof. Fulya Ağaoğlu is a board-certified professor of medicine with a distinguished career in oncology. Promoted to Professor in 2013, she brings deep academic expertise and a strong clinical focus. Since 2017 she has been affiliated with Acıbadem Health Group, where she combines patient care, research and education. Her professional memberships include the Turkish Oncology Association, the Turkish Society of Radiation Oncology and the Thoracic Oncology Society, reflecting her active engagement with the oncology community and commitment to advancing cancer care. Colleagues and patients recognize her for clinical excellence, teaching dedication and collaborative approach to multidisciplinary cancer treatment.
Education
- 2013 Professor
- 2006 Associate Professor
- 1997 Istanbul University Istanbul Faculty of Medicine Radiation Oncology
- 1993 Istanbul University Istanbul Faculty of Medicine
Experience
- 2017 Acibadem Health Group
- 2010 Oncology Institute Revenue Administration and General Administration Process Responsible
- 2009 Chief Physician of Oncology Institute
- 1995 Royal Marsden Hospital,London / Observer
Memberships
- Turkish Oncology Association
- Turkish Society of Radiation Oncology
- Thoracic Oncology Society
Publications
- 1. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors
Pediatr Hematol Oncol. 2013 Apr:30(3): 170-7 Kebudi R, Cakir FB, Gorgun 0. Agaoglu FY, Darendeliler E - Pediatric diffuse intrinsic pontine glioma patients from a single center
Childs Neiv Sysl. 2012 Dec 8. (correspondence) Kebudi R Cakir FB, Agaoglu FY, Gorgun O, Ayan I, Darendeliler E. - Sinonasal extranodal natural killer/T-cell lymphoma: a case report and review of recent developments in the management.
Journal of Otolaryngology 2012 May-Jun;22(3): 164-71 Dagoglu RN, Ozdemir 0, Ergen A.Agaoglu FY. - A review for solitary plasmacytoma of bone and extramedullary plasmacytoma.
ScienlificWorldJoumal 2012 (correspondence) Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. - Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer.
Tumor Biol. 2011 Jun:32(3):583-8. Yaman Agaoglu F, Kovancilar M, Dizdar Y. Darendeliler E, Holdenneder S. Dalay N, Gezer U. - 6. Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey.
Jpn J Clin Oncol. 2011 Dec;41(12):1380-7. A Single-center Study in Turkey.Yildiz I, Sen F, Basaran M, Ekenel M, Agaoglu F, Darendeliler E, Tune HM, Ozcan F, Bavbek S. - 7. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease.
Clin Chim Ada. 2010 Ocl 9;411(19-20):1452-6. Deligezer U, Yaman F. Darendeliler E, Dizdar Y, Holdenrieder S. Kovancilar M, Dalay N. - 8. The role of surgery and radiotherapy in treatment of soft tissue sarcomas of the head and neck region: review of 30 cases.
J Craniomaxillofac Surg. 2009 Jan;37(1):42-8. Fayda M, Aksu G, Yaman Agaoglu F, Karadeniz A, Darendeliler E, Altun M, Hafiz G. - 9. Clinical and prognostic features of plasmacytomas: a multicenter study of Turkish Oncology Group-Sarcoma Working Party.
Haydaroglu A. Turkish Oncology Group-Sarcoma Working Parly. Am J Hematol.2008 Sep;83(9):702-7. Kilciksiz S, Celik OK, Pak Y, Demiral AN, Pehlivan M, Orhan O, Tokatli F, Agaoglu F, Zincircioglu B, Atasoy BM, Ozseker N, Yersal 0, Niang U, - . Clinical outcome of rhabdomyosarcoma in adolescent and adult patients: single center experience from Turkey
Tohoku J Exp Med. 2007 Nov;213(3):221-9. Ustuner Z, Basaran M, Dizdar Y, Agaoglu FY, Bilgic B, Sakar B, Basaran GA, Darendeliler E, Ozger II, Onat H, Bavbek S.
